Sign inCreate account

Report workspace tools

NCT02721433COMPLETEDanonymous

A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study

Sponsor

Source record

Ottawa Hospital Research Institute

Phase

Source record

Phase 4

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Pamidronate, Denosumab, Zoledronate

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

Pamidronate, Denosumab, Zoledronate

Source & freshness

Source record

NCT ID

NCT02721433

Original source

ClinicalTrials.gov

Source last updated

Dec 02, 2020

Ingested at

Jun 04, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02721433

Title

A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study

Sponsor

Ottawa Hospital Research Institute

Status

COMPLETED

Phase

Phase 4

Condition raw

Breast Cancer, Prostate Cancer, Metastasis

Condition normalized

Breast Cancer, Prostate Cancer, Metastasis

Modality raw

small molecule

Modality normalized

monoclonal antibody

Target raw

Pamidronate, Denosumab, Zoledronate

Target normalized

Pamidronate, Denosumab, Zoledronate

Interventions

Pamidronate, Denosumab, Zoledronate

Public preview

Source record

The REaCT-BTA study evaluates the efficacy of 4-weekly versus 12-weekly administration of bone-targeted agents (BTAs) in improving quality of life and reducing skeletal-related events in patients with bone metastases from castration-resistant prostate cancer or breast cancer. The trial was conducted by the Ottawa Hospital Research Institute and completed in April 2020 with 263 enrolled participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02721433

Status

COMPLETED

Phase

Phase 4

Sponsor

Ottawa Hospital Research Institute

Executive brief

Investment-Ready Snapshot

The REaCT-BTA study evaluates the efficacy of 4-weekly versus 12-weekly administration of bone-targeted agents (BTAs) in improving quality of life and reducing skeletal-related events in patients with bone metastases from castration-resistant prostate cancer or breast cancer. The trial was conducted by the Ottawa Hospital Research Institute and completed in April 2020 with 263 enrolled participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 02, 2020
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02721433

Indication

Breast Cancer

Modality

monoclonal antibody

Target

Pamidronate, Denosumab, Zoledronate

Intervention

Pamidronate, Denosumab, Zoledronate

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.